Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trial

Intellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder.

The trial showed an 87% reduction in swelling attacks compared with placebo over roughly six months, and 62% of patients experienced no attacks or need for additional therapy versus 11% on placebo.

The company said the safety profile was favorable, with only mild to moderate infusion reactions, headache and fatigue. Intellia has started a rolling U.S. regulatory filing and aims to launch the product in the first half of 2027; its shares rose about 5% after the announcement.